Home / Managing Editor, Diabetes in Control (page 117)

Managing Editor, Diabetes in Control

Test Your Knowledge Question #798

Test Your Knowledge

A 43-year old patient with a 2-year history of type 2 diabetes presents to your office for a follow-up visit. She is a highly motivated patient and doesn’t have any significant co-morbidities, so together, you have set a target A1C= 6.5%. Her current medications are metformin and sulfonylurea. Despite her good efforts, her current A1C is 7.3%. You would like to add a third agent to her regimen, however she is concerned about any additional weight gain as she has gained a few pounds since starting the sulfonylurea. Which drug class would you add to minimize any additional weight gain? A. Basal insulin B. GLP-1 agonist C. Thiazolidine D. DPP-4 Inhibitor Follow link to take the test!

Read More »

Imperium: World’s First Instant Insulin Patch

Unilife Corporation has launched the world’s first instant insulin patch, Imperium. Imperium is a prefilled, preassembled, multi-day wearable insulin pump for continuous subcutaneous insulin infusion and on-demand bolus delivery through the push of a button. It is equipped with Bluetooth connectivity to wirelessly connect with smartphone apps for patient reminders …

Read More »

Smart Blood Glucose Meter to Help Diabetes Patients

Patients with diabetes have to monitor their blood glucose at home until the next doctor’s appointment. Smart blood glucose meter provides patients with easy access to certified diabetes educator and avoid future diabetes complications, according to Jodi Pulizzi, RN, BSN, CDE, CHC, director of clinical services for Livongo Health, based …

Read More »

Discontinuation of TZD Reduces Fracture Rates

Managing stress

Thiazolidinediones (TZDs), rosiglitazone and pioglitazone, have been shown to increase fracture risk in women after a year of TZD use; however, there has been little data available on the effects of the discontinuation of TZD. This longitudinal observational cohort study used data from an ancillary study of skeletal health within …

Read More »

Finerenone Improves Albuminuria in Diabetic Nephropathy Patients

Mineralocorticoid receptor antagonists (MRAs) are often used with a renin-angiotensin system (RAS) blocker to further reduce proteinuria in patients with CKD. However, eplerenone and spironolactone increase the risk of hyperkalemia in these patients. Finerenone (BAY94-8862) is a new nonsteroidal MRA that has better receptor selectivity than spironolactone, associating with lower …

Read More »